“Europe Biosimilars Market & Pipeline Insight” Report Highlight:
Biosimilars Market Overview & Trend Analysis by Country
Biosimilars Introduction Timeline in Europe
Biosimilars Development & Market Authorization Guidelines
Biosimilars Clinical Pipeline by Phase, Indication, Company & Country
Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country
Europe Biosimilars Pipeline: 93 Biosimilars
Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine)
“Europe Biosimilars Market & Pipeline Insight” Report Highlight:
Biosimilars Market Overview & Trend Analysis by Country
Biosimilars Introduction Timeline in Europe
Biosimilars Development & Market Authorization Guidelines
Biosimilars Clinical Pipeline by Phase, Indication, Company & Country
Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country
Europe Biosimilars Pipeline: 93 Biosimilars
Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine)
Europe biosimilars market opportunity outlook 2020KuicK Research
“Europe Biosimilars Market Opportunity Outlook 2020” Report Highlight:
Europe Biosimilars Market Outlook
Europe Biosimilars Market Trend Analysis by Country
Introduction of Biosimilars in European Market by Segment
Clinical & Non Clinical Guidelines
Europe Biosimilar Clinical Pipeline by Country, Company, Indication & Phase
Europe Biosimilar Clinical Pipeline: 109 Biosimilars
Clinical Insight of Biosimilars Marketed in Europe
Marketed Biosimilars in Europe: 20 Biosimilars
Download Global biosimilars market regulations & pipeline insightKuicK Research
“Global Biosimilars Market Regulations & Pipeline Insight 2014” Report Highlights:
Market Overview
Detailed Regulatory Pathways For 12 Countries/Regions
Global Biosimilars Pipeline by Phase, Indication, Company & Country
Biosimilars Pipeline: 276 in Development Phase
Majority Biosimilars in Preclinical Phase: 76 Biosimilars
Marketed Biosimilars by Indication, Company & Country: 113 Biosimilars
“Europe Biosimilars Market & Pipeline Insight” Report Highlight:
Biosimilars Market Overview & Trend Analysis by Country
Biosimilars Introduction Timeline in Europe
Biosimilars Development & Market Authorization Guidelines
Biosimilars Clinical Pipeline by Phase, Indication, Company & Country
Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country
Europe Biosimilars Pipeline: 93 Biosimilars
Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine)
Europe biosimilars market opportunity outlook 2020KuicK Research
“Europe Biosimilars Market Opportunity Outlook 2020” Report Highlight:
Europe Biosimilars Market Outlook
Europe Biosimilars Market Trend Analysis by Country
Introduction of Biosimilars in European Market by Segment
Clinical & Non Clinical Guidelines
Europe Biosimilar Clinical Pipeline by Country, Company, Indication & Phase
Europe Biosimilar Clinical Pipeline: 109 Biosimilars
Clinical Insight of Biosimilars Marketed in Europe
Marketed Biosimilars in Europe: 20 Biosimilars
Download Global biosimilars market regulations & pipeline insightKuicK Research
“Global Biosimilars Market Regulations & Pipeline Insight 2014” Report Highlights:
Market Overview
Detailed Regulatory Pathways For 12 Countries/Regions
Global Biosimilars Pipeline by Phase, Indication, Company & Country
Biosimilars Pipeline: 276 in Development Phase
Majority Biosimilars in Preclinical Phase: 76 Biosimilars
Marketed Biosimilars by Indication, Company & Country: 113 Biosimilars
Securing the Global Pharmaceutical Supply Chain against the Threat of Counter...Yasmin AbdelAziz
In 2012, counterfeit versions of the cancer drug
Avastin were found in 19 American treatment
centers. The impostor drug lacked the active
ingredient, rendering it virtually useless for
treatment purposes.
Global breast cancer monoclonal antibodies market outlook 2020KuicK Research
" Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" Report Highlights:
Breast Cancer Monoclonal Antibodies Mechanism
Global Breast Cancer Monoclonal Antibody Market Analysis
Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
Marketed Breast Cancer Monoclonal Antibodies: 6 mAb
Global cancer vaccine market & clinical trial insightKuicK Research
“Global Cancer Vaccine Market & Clinical Trial Insight” Report Highlights:
Global Cancer Market Overview
Emergence of Personalized Cancer Vaccines
Platforms for Cancer Vaccines Delivery
Mechanism of Cancer Vaccines
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 298 Vaccines
Marketed Cancer Vaccines: 15 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing
Securing the Global Pharmaceutical Supply Chain against the Threat of Counter...Yasmin AbdelAziz
In 2012, counterfeit versions of the cancer drug
Avastin were found in 19 American treatment
centers. The impostor drug lacked the active
ingredient, rendering it virtually useless for
treatment purposes.
Global breast cancer monoclonal antibodies market outlook 2020KuicK Research
" Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" Report Highlights:
Breast Cancer Monoclonal Antibodies Mechanism
Global Breast Cancer Monoclonal Antibody Market Analysis
Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
Marketed Breast Cancer Monoclonal Antibodies: 6 mAb
Global cancer vaccine market & clinical trial insightKuicK Research
“Global Cancer Vaccine Market & Clinical Trial Insight” Report Highlights:
Global Cancer Market Overview
Emergence of Personalized Cancer Vaccines
Platforms for Cancer Vaccines Delivery
Mechanism of Cancer Vaccines
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 298 Vaccines
Marketed Cancer Vaccines: 15 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing
China nuclear power sector opportunity analysisKuicK Research
“China Nuclear Power Sector Opportunity Analysis” Report Highlight:
China Power Sector Overview
China Nuclear Power Sector Overview
China Nuclear Power Sector Installed & Projected Capacity
Nuclear Fuel Procurement Overview
Insight on Existing & Upcoming Nuclear Plants
China Nuclear Power Sector Regulatory Landscape
China Nuclear Power Plant Infrastructure & Technology
China Emerging Exporter of Nuclear Reactor Technology
Cancer nanomedicine market & pipeline insight 2015KuicK Research
“Cancer Nanomedicine Market & Pipeline Insight 2015” Report Highlight
Nanomedicine for Cancer Therapies
Cancer Nanoparticles Drug Delivery Systems Classification
Mechanism of Cancer Nanomedicine Therapy
Cancer Nanomedicine Clinical Pipeline Overview
Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Cancer Nanomedicine Clinical Pipeline: 79 Drugs
Marketed Cancer Nanomedicine: 8 Drugs
Global cancer kinase inhibitors market & pipeline insightKuicK Research
“Global Cancer Kinase Inhibitors Market & Pipeline Insight” Report Highlight:
Classification & Mechanism of Kinase Inhibitors
Cancer Kinase Inhibitors Therapy Market Overview
Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country
Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country
Patent Analysis & Orphan Designation of Kinase Inhibitors
Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs
Marketed Cancer Kinase Inhibitors: 35 Drugs
Global breast cancer vaccine clinical trial insightKuicK Research
“Global Breast Cancer Vaccine Clinical Trial Insight” Report Highlight:
Global Breast Cancer Vaccine Market Overview
Global Breast Cancer Vaccine Clinical Pipeline by Company, Phase & Country
Mechanism of Breast Cancer Vaccine & Personalized Cancer Vaccines
Detailed Clinical Insight on Breast Cancer Vaccine Pipeline: 35 Vaccines
Majority in PHASE-I Clinical Trial: 12 Vaccines
Highest Clinical Phase is PHASE-III: 2 Vaccines (NeuVax & OBI-822)
Cancer targeted therapy market & clinical insight 2015KuicK Research
“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:
Introduction & Categorization of Cancer Targeted Therapies
Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
Global Cancer Targeted Therapeutics Market Dynamics
Future Prospects of Cancer Targeted Therapies
Cancer cd antigen inhibitors market & pipeline insight2015KuicK Research
“Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015” Report Highlight:
Nomenclature & Classification of CD Antigens
Mechanism of CD Antigen Cancer Therapeutics
Cancer CD Antigen Therapy Market Overview
Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
Cancer CD Antigen Inhibitors Clinical Pipeline: 207 Drugs
Marketed Cancer CD Antigen Inhibitors: 27 Drugs
Majority of Cancer CD Antigen Inhibitors in Preclinical Phase: 70 Drugs
Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 44 Drugs
Cancer CD Antigens Clinical Pipeline is Represented in 52 Graphs & Charts
Global cancer vaccines market & pipeline analysisKuicK Research
“Global Cancer Vaccine Market & Pipeline Analysis” Report Highlights:
Global Cancer Market Overview
Personalized Cancer Vaccines: Progress & Possibilities
Platforms for Cancer Vaccines Delivery
Cancer Vaccines: Mechanism & Innovations
Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
Global Cancer Vaccine Clinical Pipeline: 289 Vaccines
Marketed Cancer Vaccines: 12 Vaccines
Regulatory Framework for Cancer Vaccines Development & Marketing
Global cancer monoclonal antibodies market & pipeline insightKuicK Research
“Global Cancer Monoclonal Antibodies Market & Pipeline Insight” Report highlights:
Cancer Monoclonal Antibodies Market Overview
Emerging Market Dynamics: Favorable Parameters, Challenges & Growth Outlook
Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country
Cancer Monoclonal Antibodies in Pipeline: 605
Majority Cancer Monoclonal Antibodies Preclinical Phase: 258
Marketed Cancer Monoclonal Antibodies: 34
Cancer Monoclonal Antibodies Patent Analysis
Global cancer stem cell therapy market outlook 2020KuicK Research
“Global Cancer Stem Cell Therapy Market Outlook 2020” Report Highlight:
Introduction & Classification of Stem Cells
Stem Cell Transplants Classification
Cancer Stem Cell Therapy Mechanism of Action
Global Cancer Stem Cell Market Analysis
Global Cancer Stem Cell Clinical Pipeline by Company & Phase
Global Cancer Stem Cell Clinical Pipeline: 32 Therapies
Global Cancer Stem Cell Market Dynamics: Challenges & Favorable Parameters
Global Cancer Stem Cell Market Future Outlook
Global diabetes drug market & pipeline insight 2015KuicK Research
"Global Diabetes Drug Market & Pipeline Insight 2015" Report Highlight:
Global Diabetes Drug Market Overview
Global Diabetic Drug Clinical Pipeline by Company & Phase
Global Diabetic Drug Clinical Pipeline: 817 Drugs
Majority in Preclinical Phase: 205 Drugs
Type 2 Diabetes Mellitus Drugs in Pipeline: 380 Drugs
Type 1 Diabetes Mellitus Drugs in Pipeline: 79 Drugs
Diabetic Nephropathies Drugs in Pipeline: 41 Drugs
Marketed Diabetic Drugs: 99 Drugs
Global gene therapy market & pipeline insightKuicK Research
“Global Gene Therapy Market & Pipeline Insight” Market Highlight:
Gene Therapy Market Overview
Significance of Gene Therapy in Cancer Therapeutics
Current Applications of Gene Therapy to Cancer Treatment
Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook
FDA & AMA Guidelines for Gene Therapy
Gene Therapy Pipeline by Phase, Indications, Country & Company
Gene Therapy Pipeline: 246 Drugs
Marketed Gene Therapy: 2 (Gendicine & Rexin-G)
Cancer Gene Therapy Pipeline: 69 Drugs
This document presents an analysis of the current state of the biosimilar market as well as its perspectives of evolution, with a particular focus on the French market
Download Global biosimilars market & pipeline insight 2018KuicK Research
Global Biosimilars Pipeline Report Highlights:
Global Biosimilars Market Overview
Global Biosimilars Market Dynamics
Regulatory Framework Across Key Markets
Biosimilar Clinical Pipeline Insight by Indication, Country & Phase
Marketed Biosimilars Profiles by Indication & Country
Competitive Landscape
Biopharmaceuticals are medicinal drugs which are produced through biotechnology methods such as recombinant DNA techniques, fermentation, hybridoma techniques, and purification processes. Biopharmaceutical production involves the usage of biological sources, either live organisms or their active components. They are made up of proteins and nucleic acids and target specific diseases and patients groups. Biopharmaceuticals are used in the treatment of various chronic diseases such as cardiovascular, metabolic, neurological, cancer, and other rare diseases for which there are no available treatments.
Executive Summary:Regulation Issues on the development of BiosimilarsJoseph Pategou
Nowadays patients and physicians can have access to three types of drugs: a originators, a generic or a biosimilar.
Those drugs have different regulatory systems that apply in Europe; moreover the biosimilars regulation is evolving and may change. Regulation is an important factor that can give more confidence to patients and healthcare professionals. As a consequence, biosimilaires will grow.
Us biosimilars market opportunity & clinical pipeline analysisRajesh Sarma
“US Biosimilars Market Opportunity & Clinical Pipeline Analysis” Report Highlight:
US Biosimilars Market Introduction
US Biosimilars Regulatory Scenario
Unique Features of US Biosimilars Market
Impact of Biosimilars in US Market
Impact of Reimbursement Policies on US Biosimilars Market
Zarxio: First Approved Biosimilar in US
US Biosimilar Clinical Pipeline By Company, Indication & Phase
US Biosimilar Clinical Pipeline: 104 Biosimilars
Marketed Biosimilars: 1 Biosimilar
Download Us biosimilars market opportunity & clinical pipeline analysisKuicK Research
“US Biosimilars Market Opportunity & Clinical Pipeline Analysis” Report Highlight:
* US Biosimilars Market Introduction
* US Biosimilars Regulatory Scenario
* Unique Features of US Biosimilars Market
* Impact of Biosimilars in US Market
* Impact of Reimbursement Policies on US Biosimilars Market
* Zarxio: First Approved Biosimilar in US
* US Biosimilar Clinical Pipeline By Company, Indication & Phase
* US Biosimilar Clinical Pipeline: 104 Biosimilars
* Marketed Biosimilars: 1 Biosimilar*
Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players.
Global orphan drug market outlook 2018Rajesh Sarma
“Global Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to global orphan drug market:
Global & Regional Orphan Drug Market Overview
Orphan Drug Designation Criteria Across Key Markets
Market Specific Reimbursement Policy & Regulatory Framework
Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country
Competitive Landscape
Biopharmaceuticals product segments analyzed in this study comprises Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and others. Therapeutic areas analyzed include Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and others. Biopharmaceuticals market, estimated at US$199.7 billion globally in 2013, is further projected to reach US$497.9 billion by 2020, growing at 13.5% CAGR between 2010 and 2020. Among different product segments, monoclonal antibodies (moAb) constitutes the largest product segment in the global biopharmaceuticals market accounting for an estimated share of 25.6% in 2013, equating to US$51.1 billion. In terms of therapeutic area, neurology applications is the largest market for global biopharmaceuticals with an estimated 2013 share of 28.2% valued at US$56.3 billion, and further expected reach a projected US$144.5 billion by 2020.
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Aiswariya Chidambaram
This presentation which highlights the key market and technology trends in the global biopharmaceutical contract manufacturing market was delivered as a lecture at the In-Focus Seminar session at CPhI Worldwide 2013 held at Frankfurt, Germany.
Multiple myeloma therapeutics in major developed markets to 2021 growth dri...David2591
Most up-to-date research on "Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments" to its huge collection of research reports.
At least 400 million people worldwide lack access to essential health services and 2 billion cannot afford the medicines they need. Meanwhile, the global cost of healthcare has jumped to 6.5 trillion US dollars. Access is a huge and complex issue, which affects both developing and developed countries.
Today Carol Lynch, our Global Head of Biopharmaceuticals, gave a keynote address to the European Biosimilars Group highlighting how biosimilars can help transform patient outcomes and calling for all stakeholders to work together to build trust and confidence. You can read the presentation here
Similar to Europe biosimilars market & pipeline insight (20)
Global cancer cdk inhibitors market & clinical pipeline outlook 2022KuicK Research
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report highlights:
* Selectivity and Working Mechanism of a Cancer CDKs Inhibitor
* Recent Advances in the CDKs Related Cancer Therapy
* Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline
* Market Opportunity Assessment: More Than US$ 20 Billion (2022)
* Price Analysis of Cancer CDKs Inhibitors:
* Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017)
Cd antigen cancer therapy market outlook & clinical trials insight 2023KuicK Research
“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report highlights:
• Market Opportunity Assessment: More than US$ 60 Billion by 2023
• Clinical & Patent Insight on 17 Commercialize CD Antigen Drugs
• Clinical & Licensing Insight on 184 CD Antigens in Clinical Pipeline
• Dosage & Price Analysis on Key Drugs
• Mechanism of CD Antigen Cancer Therapeutics
• Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
• Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
Global orphan drug market designation status clinical pipeline trials insigh...KuicK Research
“Global Orphan Drug Market & Clinical Pipeline Insight 2023” Report Highlights:
• Clinical Insight on 800 Orphan Drugs
• Patent Insight, Orphan Designated Indication & Region/Country
• Marketed Orphan Drugs: More Than 300
• Maximum Orphan Designated Drugs in Phase-II: More Than 200
• Global Orphan Drug Designation Criteria
• FDA & EMA Guidelines
“US Shale Gas Industry Analysis” Report Highlight:
* US Shale Gas Industry Overview
* Shale Gas Exploration, Technical and Technology Aspects
* US Shale Gas Reserve Analysis: Technical & Recoverable Reserves
* Investments in Shale Gas Exploration & Production
* US Shale Gas Sector Dynamics
* Shale Boom to Drive LNG Export Projects
Download Uae nuclear power sector opportunity analysisKuicK Research
“UAE Nuclear Power Sector Opportunity Analysis” Report Highlight:
* UAE Energy Policy beyond Oil & Gas
* UAE Nuclear Power Sector Overview
* UAE Nuclear Power Sector Dynamics
* Nuclear Power Sector Management & Regulatory Framework
* Nuclear Power Sector Regulations
* Details of Nuclear Power Plants in UAE
* UAE Nuclear Power Sector Future Outlook
Download Turkey wind power sector outlook 2017KuicK Research
“Turkey Wind Power Sector Outlook 2017” gives comprehensive insight on following aspect related to wind power sector development in Turkey:
* Wind Power Sector Overview
* Wind installed Capacity & Generation
* Operating Wind Farms by Province & Company
* Onshore & Offshore Wind Potential
* Emerging Trends
* Policy Framework
* Competitive Landscape
Download South korea wind power sector analysis 2013KuicK Research
“South Korea Wind Power Sector Analysis 2013” research report discusses following aspect related to emerging wind power sector in South Korea:
* Current Sector Trends
* Onshore & Offshore Wind Potential
* Wind Power Sector Indicators
* Operating Wind Farms
* Future Outlook & Sector Emerging Trends
* Regulatory & Policy Framework
* Competitive Landscape
Download Saudi arabia airport privatization opportunity outlook 2022KuicK Research
“Saudi Arabia Airport Privatization Opportunity Outlook 2022” report highlights:
Saudi Arabia Aviation Industry Overview
Privatization in Saudi Arabia
Investment and Expansion Opportunities for International Investors
Civil Aviation Laws and Policies Framework
Ongoing Privatization Projects
Privatization Build - Operateandndash;Transfer (BOT) Business Model
Download Non hodgkin lymphoma therapeutics market & pipeline insightKuicK Research
“Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight” Report Highlight:
Global Non Hodgkin Lymphoma Market Overview
Mechanism of Non Hodgkin Lymphoma Therapeutics
Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company
Global Non Hodgkin Lymphoma Pipeline: 204 Drugs
Majority of the Drugs are in Phase-I: 54 Drugs
Marketed Drugs for Non Hodgkin Lymphoma: 30 Drugs
Patent Analysis by Country, Year & Compositions
Download Nanoparticle drug delivery market & clinical pipeline insightKuicK Research
“Nanoparticle Drug Delivery Market & Clinical Pipeline Insight” Report Highlights:
Nanoparticle Drug Delivery Market Overview
Nanoparticle Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 190
Majority of Nanoparticle Drug in Preclinical Phase: 70
Marketed Nanoparticle Drugs: 12
Suspended & Discontinued Drug Profiles
Download Japan generics drug market outlook 2020KuicK Research
“Japan Generics Drug Market Outlook 2020” Report Highlights:
Introduction to Japanese Generic Drug Market
Attractiveness of Japanese Generic Market
Super Generics in Japan
Japan Healthcare System & Generic Drugs
Different Parameters for Generic & Branded Drugs
Comparison of Generic Drugs in US & Japan
Japan Generics Drug Market Analysis
Japan Generics Drug Market Future Prospects
Download India urban and industrial waste to energy marketKuicK Research
The Urban and Industrial waste based power projects have been witnessing upward trend in recent years driven by increasing investments from private sector and ongoing government initiatives to promote generation of power from urban and industrial waste. The overall installed capacity of grid connected waste power projects surpassed 70 MW by end of 2011 as compare to more than 90 MW of off grid waste base power projects.
Considering the huge potential to convert waste to energy in India, the Ministry of Environment and Forests had formulated the Municipal Solid Wastes Management and Handling Rules in 2000. Waste to Energy is understood as a renewable technology, and comes under the overall guidance and facilitation of the Ministry of Non Renewable Energy of India, which has announce finacila incentives and assistance programme in.
Download India nuclear power sector generation and investment opportunity out...KuicK Research
“India Nuclear Power Sector Generation and Investment Opportunity Outlook 2032” report highlights:
India Nuclear Power Sector Overview
India Nuclear Power Sector Indicators
India Existing and upcoming Nuclear Power Plants Overview
Indian Nuclear Power Regulatory and Policy Framework
India Nuclear Power Plants Infrastructure
India Nuclear Fuel Supply Scenario
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Europe biosimilars market & pipeline insight
1. Europe Biosimilars Market & Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 1
Biosimilars have emerged as one of the most promising segment of the European
pharmaceutical industry in recent years. The biosimilars segment has been experiencing a
steady growth driven by patent expiration of blockbuster drugs, amenable regulatory
framework, economic incentives along with favorable pricing and reimbursement policies
adopted across multiple markets in Europe. The current biosimilars market is highly
fragmented in nature due to their accessibility in various therapeutic categories. The
European biosimilars market is divided into various categories: Granulocyte-colony stimulating
factor (G-CSF or GCSF), erythropoiesis-stimulating agents (ESAs) and somatropin biosimilars,
Insulin, mAbs and follitropin. The present market fragmentation is driven by the availability
of particular biosimilar products which were introduced over a decade ago. These products
created niche among them and resulted in inclination toward a particular segments over a
period of time.
One of the most promising factors responsible for the development of biosimilars market is
the patent expiration of reference drugs. The European biosimilars market is experiencing
tremendous growth as blockbuster biologic drugs are going off-patent. The entry of new
biosimilars due to patent expiry into various therapeutic indications has created a new
category for the biosimilars. For instance, Ely Lily and Boehringer Ingelheim have already got
marketing authorization of their biosimilar insulin in June’2014 even as the current diabetes
drug (Lantus) marketed by Sanofi will go off patent in February’2015.
The competitive pricing and reimbursement policies adopted by country specific regulators
are also promoting the introduction of biosimilars in European market. The newly introduced
biosimilars are approximately 20-30% cheaper and hence results in high level of acceptability
among patients and physicians in comparison to originator molecule. The benefits of using the
biosimilars include reimbursement provided by many governments which further decreases
the financial burden from the patients as result of which they do not revert to originator
molecules.
Currently there are 18 biosimilars available in European market and more than 90 are in
multiple phases of development in clinical pipeline. Majority of the available biosimilars are
approved for the treatment of indication like Cancer, Kidney Failure and Anemia. Approved
Biosimilars in Europe:
2. Europe Biosimilars Market & Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 2
Abseamed (epoetin alfa), Bemfola (follitropin alfa), Binocrit (epoetin alfa), Biograstim
(filgrastim), Epoetin Alfa Hexal (epoetin alfa), Filgrastim Hexal (filgrastim), Grastofil
(filgrastim), Inflectra (infliximab), Nivestim (filgrastim), Omnitrope (somatropin),
Ovaleap (follitropin alfa), Ratiograstim (filgrastim), Remsima (infliximab), Retacrit (epoetin
zeta), Silapo (epoetin zeta), Tevagrastim (filgrastim), Zarzio (filgrastim), Wepox (epoetin
alfa)
“Europe Biosimilars Market & Pipeline Insight” Report Highlight:
• Biosimilars Market Overview & Trend Analysis by Country
• Biosimilars Introduction Timeline in Europe
• Biosimilars Development & Market Authorization Guidelines
• Biosimilars Clinical Pipeline by Phase, Indication, Company & Country
• Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country
• Europe Biosimilars Pipeline: 93 Biosimilars
• Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine)
For Report Sample Contact: neeraj@kuickresearch.com
3. Europe Biosimilars Market & Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 3
Table of Contents
1. Europe Biosimilars Market Overview
1.1 Current Market Scenario
1.2 Biosimilars Clinical Pipeline Overview
2. Europe Biosimilars Market Trend Analysis by Country
2.1 Austria
2.2 Belgium
2.3 France
2.4 Germany
2.5 Hungary
2.6 Italy
2.7 Norway
2.8 Poland
2.9 Spain
2.10 Sweden
2.11 Switzerland
2.12 UK
3. Biosimilars Introduction Timeline in Europe
3.1 Growth Hormones in 2006
3.2 Epoetin in 2007
3.3 G-CSF in 2008
3.4 Monoclonal Antibodies in 2013
3.5 Follitropin in 2013
4. Europe Biosimilars Market & Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 4
3.6 Insulin in 2015
4. Europe Biosimilars Risk Management Planning & Safety Regulation Scenario
5. Europe Biosimilars Market Dynamics
5.1 Favorable Market Parameters
5.1.1 Bolar Provisions Supporting Biosimilars Development
5.1.2 Patent Expiry to Tap European Biosimilars Markets
5.1.3 Reimbursement Policies
5.1.4 Increasing Level of Investments
5.1.5 Manufacturing Capabilities
5.1.6 R&D Expertise
5.2 Market Growth Challenges
6. Future Prospectus of Biosimilars in Europe
7. Regulatory & Approval Authorities: EMA & CHMP
8. Biosimilars Development & Market Authorization Guidelines
8.1 Development of Similar Biological Medicinal Products Containing r-hFSH
8.2 Similar Biological Medicinal Products Containing Interferon Beta
8.3 Immunogenicity Assessment of Monoclonal Antibodies Intended For In Vivo Clinical Use
8.4 Similar Biological Medicinal Products Containing Monoclonal Antibodies
8.5 Similar Biological Medicinal Products Containing Recombinant Erythropoietins
8.6 Similar Medicinal Products Containing Recombinant Human Soluble Insulin
8.7 Similar Medicinal Products Containing Somatropin
8.8 Similar Biological Medicinal Products Containing Biotechnology Derived Proteins as
Active Substance
8.9 Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins
5. Europe Biosimilars Market & Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 5
8.10 Comparability of Biotechnology-Derived Medicinal Products After A Change
In The Manufacturing Process
9. Europe Biosimilars Clinical Pipeline by Phase, Indication, Company & Country
9.1 Unknown
9.2 Research
9.3 Preclinical
9.4 Clinical
9.5 Phase-I
9.6 Phase-I/II
9.7 Phase-II
9.8 Phase-III
9.9 Preregistration
9.10 Registered
10. Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country
11. No Development Reported in Biosimilars Clinical Pipeline
11.1 No Development Reported
11.2 Discontinued
12. Competitive Landscape
12.1 Apotex
12.2 Celltrion Healthcare
12.3 Hexal
12.4 Hospira
12.5 Finox Biotech
12.6 Medice Arzneimittel Pütter
12.7 Sandoz
6. Europe Biosimilars Market & Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 6
12.8 Stada Arzneimittel
12.9 Teva Pharma
List of Figures
Figure 1-1: Europe-Biosimilars Market Opportunity (US$ Million), 2014-2020
Figure 1-2: Factors Responsible for Growth of Biosimilars Market in Europe
Figure 1-3: Europe Biosimilar Pipeline by Phase (%), 2014
Figure 1-4: Europe Biosimilar Pipeline by Phase (Number), 2014
Figure 1-5: No Development Reported in Biosimilar Pipeline by Phase (%), 2014
Figure 1-6: No Development Reported in Biosimilar Pipeline by Phase (Number), 2014
Figure 1-7: Suspended Biosimilar Pipeline by Phase (%), 2014
Figure 1-8: Suspended Biosimilar Pipeline by Phase (%), 2014
Figure 3-1 Biosimilar Product Approval Timeline in Europe
Figure 3-2: Europe Biosimilars Market Emerging Segment
Figure 3-3: Approved Biosimilars by Segment
Figure 3-4: HGH Biosimilars Approved & Available in European Market
Figure 3-5: EPO Biosimilars Approved & Available in European Market
Figure 3-6: G-CSF Biosimilars Approved & Available in European Market
Figure 3-7: mAbs Biosimilars Approved & Available in European Market
Figure 3-8: Follitropin Biosimilars Approved & Available in European Market
Figure 3-9: Insulin Biosimilars Approved & Available in European Market
Figure 4-1: Safety Evaluation of Biosimilars after Marketing Approval in Europe
Figure 4-2: Risk Management of Biosimilars
7. Europe Biosimilars Market & Pipeline Insight
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 7
Figure 4-3: Overview of Demonstrating Biosimilarity
Figure 5-1: Bolar Provision for the Development of Biosimilars in Europe
Figure 5-2: Effects of Reimbursement Policies on Healthcare System
Figure 5-3: Available Biosimilars in Market by Company & Segment
Figure 5-4: Drivers for Success in European Biosimilars Market
Figure 5-5: Market Growth Challenges
Figure 7-1: Regulatory Timeline for the Approval of Biosimilars
Figure 7-2: Schematic Overview of Biosimilar Approval in EU
Figure 7-3: Biosimilars Development Process
For Report Sample Contact: neeraj@kuickresearch.com